The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | AML: Vaccination, hypomethylation and CAR-T
David Avigan, MD, Harvard Medical School, Boston, MA, discusses the efficacy of using hypomethylating agents to increase the potency of dendritic cell hybridoma acute myeloid leukemia (AML) vaccines. Dr Avigan also discusses how the combination of the aforementioned vaccine with CAR T-cell therapy may offer a potentially powerful therapy for patients. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
